Conference Coverage

1-16 of 60

Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
- Ryan Quigley
- Kathrin M. Bernt, MD
- Rushabh Mehta, BS
- Fatemeh Alikarami
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Project Oncology®
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
- Pavani Chalasani, MD, MPH
- Erica L. Mayer, MD, MPH
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Project Oncology®
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
- Pavani Chalasani, MD, MPH
- Erica L. Mayer, MD, MPH
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Project Oncology®
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
- Jacob Sands, MD
- Aaron Lisberg, MD
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Project Oncology®
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
- Jacob Sands, MD
- Julia Rotow, MD
- Xiuning Le, MD, PhD
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Project Oncology®
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
- Victoria Coleman-Cowger, PhD
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
- Ryan Quigley
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
- Ryan Quigley
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Project Oncology®
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
- Jun-ichi Abe, MD, PhD
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
- Ryan Quigley
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's Roundtable
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
- David Feller-Kopman, MD
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
- Hallie Blevins, PhD.